Tag Archives: Antibiotic research and development

“C. diff. Spores and More ™” C diff Radio Returns To Live Broadcasting Tuesday, January 19th

cdiffRadioLogoMarch2015

 

Welcome to Season 2

C. diff. Spores and More ™”

Join us for live broadcasting  on Tuesday January 19th, 2016 at 10 a.m. Pacific Time,
11 a.m. Mountain Time, 12 p.m. Central Time,   1 p.m. Eastern Time.

 

Programming for Tuesday, January 19th:
“C. difficile Infections; The What, Where and How.”

This episode of “C. diff. Spores and More” is focused on
“C. difficile Infections; The What, Where and How.”
What is it,  What can be done to prevent acquiring it,
Where is it acquired, Where can clinicians and patients
learn more about this infection, How is it being prevented at home
and in the hospitals, How CDI’s are being treated, and How to learn more about the
prevention, treatments, and environmental safety products available
With our special guests:

oneto_for_the_web

 

 

Dr. Caterina Oneto,, MD

 

drPaulfeuerstadt

 

 

 

 

and Dr. Paul Feuerstadt, MD,
Both professors and physicians specializing in Gastroenterology with
a wealth of knowledge and experience treating patients
with a CDI and through ongoing scientific/medical research.

 

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

 

caralla-Promo-Health

 Click Image Above to Listen to Archived Shows

 

We are pleased to share  “C. diff. Spores and More ™”  with you because, as advocates
of C. diff., we know the importance of this cutting-edge new weekly radio show
and what it means for our Foundation’s community worldwide.

Hard Facts: Deaths and illnesses are much higher than reports have shown Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released today, February 25, 2015, by the Centers for Disease Control and Prevention (CDC).

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

Previous studies indicate that C. diff. has become the most common
microbial cause of Healthcare-Associated Infections found in U.S. hospitals
driving up costs to $4.8 billion each year in excess health care costs in acute
care facilities alone. Approximately two-thirds of C. diff. infections
were found to be associated with an inpatient stay in a health care facility,
only 24% of the total cases occurred in patients while they were hospitalized.
The study also revealed that almost as many cases occurred in nursing homes as
in hospitals and the remainder of individuals acquired the
Healthcare-Associated infection, C. diff., recently discharged from
a health care facility.

This new study finds that 1 out of every 5 patients with the
Healthcare-Associated Infection (HAI), C. diff., experience
a recurrence of the infection and 1 out of every 9 patients over the
age of 65 diagnosed with a HAI – C. diff. infection died
within 30 days of being diagnosed. Older Americans are quite vulnerable
to this life-threatening diarrhea infection. The CDC study also found
that women and Caucasian individuals are at an increased risk of
acquiring a C. diff. infection.
The CDC Director, Dr. Tom Frieden, MD, MPH said, “C. difficile
infections cause immense suffering and death for thousands of Americans
each year.” “These infections can be prevented by improving antibiotic
prescribing and by improving infection control in the health care system.
CDC hopes to ramp up prevention of this deadly infection by supporting
State Antibiotic Resistance Prevention Programs in all 50 states.”

“This does not include the number of C. diff. infections taking place
and being treated in other countries.”  “The  C Diff Foundation supports hundreds
of communities by sharing the Foundation’s mission and
Raising C. diff. awareness to healthcare professionals,patients,
families,  and communities working towards a shared goal ~  witnessing a
reduction of newly diagnosed C. diff. cases by 2020 .”
” The C Diff Foundation volunteer Advocates are truly appreciated and stand
with the Foundation members creating positive changes through
time and dedication in “Raising C. diff. awareness ™”  worldwide.

C. diff. Spores and More ™“ spotlights world
renowned topic experts, research scientists, healthcare professionals,
organization representatives, C. diff. survivors, board members,
and C Diff Foundation volunteer advocates  – all working together to
create positive changes in the C. diff. community and more.

Through their interviews, the C Diff Foundation mission will
connect, educate, and empower our worldwide listeners.

Do you have Questions?  Email them to the C Diff Foundation at

info@cdifffoundation.org or through the show page portal.
Questions will be addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,
Dr. Fred Zar is a Professor of Clinical Medicine,
Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency
at the University of Illinois at Chicago.  Over the last two decades he has
been a pioneer in the study of the treatment of Clostridium difficile disease
and the need to stratify patients by disease severity.

 

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)

 

 

CloroxHealthcare_72

Programming for “C. diff. Spores and More ™”   is made
possible through our official Corporate Sponsor;  Clorox Healthcare™

Click on the Clorox Healthcare Logo to visit their website.

New Antibiotic may treat “superbugs”

Microscope - 5Bacterial infections are hard to fight. It’s not just that there are superbugs which resist antibiotics, like MRSA (Methicillin-Resistant Staphylococcus aureus)  – it is that the methods for finding effective antibiotics aren’t very efficient.

“The compound is highly potent against a broad range of Gram-positive microbes, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE),” the company said in a statement.

The Centers for Disease Control and Prevention says more than two million people are infected by drug-resistant germs each year, and 23,000 die of their infections. The biggest killer by far in the U.S. is diarrhea-causing C. difficile.

However, scientists have developed a technique that harnesses environmental bacteria to find antimicrobial weapons much more quickly. Their approach uses a mix of moistened soil, liquid agar (bacterial culture) and diluted bacterial samples to isolate microbes for study while giving them the natural conditions they need to grow. At least in theory, medical researchers no longer have to limit their antibiotic development to bacteria that survive in lab conditions. If it grows in dirt, it’s a candidate.

The team behind the new method has already produced a very promising antibiotic, teixobactin.

It not only kills certain kinds of harmful bacteria (namely those with cellular walls, like anthrax and tuberculosis), but makes it difficult for those bugs to evolve resistance. It’ll be a while before teixobactin is a practical treatment, and it won’t be useful in many other circumstances. But that’s almost beside the point — thanks to the new research technique, it’s no longer far fetched to think that humans can stay one step ahead of sickness-inducing organisms.

For additional information; click on the link below:

www.nbcnews.com/health/health-news/common-dirt-new-antibiotic-may-conquer-superbugs-n281011